Skip to content

Study · Randomized controlled trial · 2026

9 results

Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial.

Prasad TN, Pal R, Bhadada SK, Ram S, Singla V, Pulami S

The Journal of clinical endocrinology and metabolism1 Apr 2026Cited by 1 (Europe PMC)

PMID41183496 (opens in a new tab)DOI10.1210/clinem/dgaf589 (opens in a new tab)PepBankPUB-41183496
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, teriparatide significantly improved tibial total volumetric BMD.

    In plain wordsIn postmenopausal women with T2D, teriparatide improved tibial total volumetric bone density.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial total volumetric BMD
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius).
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, teriparatide significantly improved radial total volumetric BMD.

    In plain wordsIn postmenopausal women with T2D, teriparatide improved radial total volumetric bone density.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial total volumetric BMD
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius).
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, teriparatide significantly improved tibial trabecular volumetric BMD.

    In plain wordsIn postmenopausal women with T2D, teriparatide improved tibial trabecular volumetric bone density.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial trabecular volumetric BMD
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius).
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, teriparatide significantly improved radial trabecular volumetric BMD.

    In plain wordsIn postmenopausal women with T2D, teriparatide improved radial trabecular volumetric bone density.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial trabecular volumetric BMD
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius).
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, teriparatide significantly improved trabecular number.

    In plain wordsIn postmenopausal women with T2D, teriparatide improved trabecular number.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular number
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius).
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, teriparatide significantly improved tibial trabecular bone volume fraction.

    In plain wordsIn postmenopausal women with T2D, teriparatide improved tibial trabecular bone volume fraction.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial trabecular bone volume fraction
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius).
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, teriparatide significantly improved radial trabecular thickness.

    In plain wordsIn postmenopausal women with T2D, teriparatide improved radial trabecular thickness.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial trabecular thickness
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius).
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, strength parameters remained unchanged with teriparatide.

    In plain wordsIn postmenopausal women with T2D, estimated bone strength measures did not change with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeMicrofinite element strength parameters
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Microfinite element analysis-derived strength parameters were unchanged, except for a modest increase in tibial stiffness with denosumab.
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with T2D, bone turnover markers increased with teriparatide, with an anabolic window by 6 weeks.

    In plain wordsIn postmenopausal women with T2D, teriparatide increased bone turnover markers, with an anabolic window by 6 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone turnover markers
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg dailyAs given in this study (human).

    Source sentences

    Summary
    BTMs decreased with antiresorptives, increased with teriparatide, and showed an anabolic window by 6 weeks.
    3 context sentences
    Summary · context
    Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).
    Summary · context
    Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks.
    Summary · context
    The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.